Cargando…

Immunotherapy in inoperable stage III non-small cell lung cancer: a review

The leading cause of cancer-related deaths in the United States continues to be lung cancer. Approximately 25–30% of patients are diagnosed with locally advanced non-small cell lung cancer (NSCLC). Concurrent chemoradiation with a platinum-based doublet is the current standard of care for patients w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jain, Natasha A, Otterson, Gregory A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioExcel Publishing Ltd 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6586171/ https://www.ncbi.nlm.nih.gov/pubmed/31258616 http://dx.doi.org/10.7573/dic.212578

Ejemplares similares

Therapeutic revolution for inoperable stage III non-small cell lung cancer in the immune era
por: Li, Jiakang, et al.
Publicado: (2022)

Can LMWH improve the outcome of patients with inoperable stage III non-small cell lung cancer?
por: Kucukoner, Mehmet, et al.
Publicado: (2012)

Pattern-of-failure and salvage treatment analysis after chemoradiotherapy for inoperable stage III non-small cell lung cancer
por: Taugner, Julian, et al.
Publicado: (2020)

Hypofractionated radiotherapy for medically inoperable stage I non‐small cell lung cancer
por: Jiang, Wei, et al.
Publicado: (2015)

Combined Radiomics–Clinical Model to Predict Radiotherapy Response in Inoperable Stage III and IV Non-Small-Cell Lung Cancer
por: Chen, Wenrui, et al.
Publicado: (2022)

Efficacy and safety of particle therapy for inoperable stage II-III non-small cell lung cancer: a systematic review and meta-analysis
por: Chen, Yanliang, et al.
Publicado: (2023)

The Evolving Role of Immunotherapy in Stage III Non-Small Cell Lung Cancer
por: Perdrizet, Kirstin, et al.
Publicado: (2021)

Hypofractionated Accelerated Concurrent Chemoradiotherapy in Inoperable Stage III Non-small Cell Lung Cancer: SOCCAR. A Large Single-Centre Experience
por: Patibandla, A., et al.
Publicado: (2020)

Percutaneous Cryoablation for the Treatment of Medically Inoperable Stage I Non-Small Cell Lung Cancer
por: Yamauchi, Yoshikane, et al.
Publicado: (2012)

Clinical Management and Outcome of Grade III Pneumonitis after Chemoradioimmunotherapy for Inoperable Stage III Non-Small Cell Lung Cancer—A Prospective Longitudinal Assessment
por: Kauffmann-Guerrero, Diego, et al.
Publicado: (2021)

Real-World Experience of Patients with Inoperable, Stage III Non-small-Cell Lung Cancer Treated with Durvalumab after Chemoradiotherapy: Indian Experience
por: Noronha, Vanita, et al.
Publicado: (2020)

Clinical results of proton beam radiotherapy for inoperable stage III non-small cell lung cancer: a Japanese national registry study
por: Tatebe, Hitoshi, et al.
Publicado: (2023)

Negativation of PD-L1 Postoperatively in Initially Inoperable Stage III Non-Small Cell Lung Cancer Treated with Pembrolizumab: Two Case Reports
por: Nasr, Fadi, et al.
Publicado: (2019)

Chemoradioimmunotherapy of inoperable stage III non-small cell lung cancer: immunological rationale and current clinical trials establishing a novel multimodal strategy
por: Käsmann, Lukas, et al.
Publicado: (2020)

Hypofractionated three-dimensional conformal radiotherapy for medically inoperable early stage non-small-cell lung cancer
por: Lee, Joo Ho, et al.
Publicado: (2013)

Percutaneous radiofrequency ablation for medically inoperable patients with clinical stage I non-small cell lung cancer
por: Liu, Baodong, et al.
Publicado: (2015)

Relationship between Treatment Plan Dosimetry, Toxicity, and Survival following Intensity-Modulated Radiotherapy, with or without Chemotherapy, for Stage III Inoperable Non-Small Cell Lung Cancer
por: Remmerts de Vries, Isabel F., et al.
Publicado: (2021)

Radical cyberknife radiosurgery with tumor tracking: an effective treatment for inoperable small peripheral stage I non-small cell lung cancer
por: Collins, Brian T, et al.
Publicado: (2009)

Identifying patterns of care for elderly patients with non-surgically treated stage III non-small cell lung cancer: an analysis of the national cancer database
por: Miller, Eric D, et al.
Publicado: (2018)

Emerging Therapies for Stage III Non-Small Cell Lung Cancer: Stereotactic Body Radiation Therapy and Immunotherapy
por: Kumar, Sameera S., et al.
Publicado: (2017)

Absence of toxicity with hypofractionated 3-dimensional radiation therapy for inoperable, early stage non-small cell lung cancer
por: Faria, Sergio L, et al.
Publicado: (2006)

Concurrent Chemoradiotherapy with Vinorelbine plus Split-Dose Cisplatin may be an Option in Inoperable Stage III Non-Small Cell Lung Cancer: A Single-Center Experience
por: Mertsoylu, Hüseyin, et al.
Publicado: (2015)

A phase II open-label multicenter study of gefitinib in combination with irradiation followed by chemotherapy in patients with inoperable stage III non-small cell lung cancer
por: Levy, Antonin, et al.
Publicado: (2016)

Implementation of durvalumab maintenance treatment after concurrent chemoradiotherapy in inoperable stage III non-small cell lung cancer (NSCLC)—a German radiation oncology survey
por: Käsmann, Lukas, et al.
Publicado: (2020)

Randomized phase II trial of S‐1 plus cisplatin or docetaxel plus cisplatin with concurrent thoracic radiotherapy for inoperable stage III non‐small cell lung cancer
por: Shimokawa, Tsuneo, et al.
Publicado: (2020)

Stereotactic Body Radiotherapy for Medically Inoperable Stage I-II Non–Small Cell Lung Cancer: The Mayo Clinic Experience
por: Hobbs, Corey J., et al.
Publicado: (2017)

Perioperative immunotherapy in stage IB-III non-small cell lung cancer: a critical review of its rationale and considerations
por: Sim, Jae Kyeom, et al.
Publicado: (2023)

Management of Resectable Stage III-N2 Non-Small-Cell Lung Cancer (NSCLC) in the Age of Immunotherapy
por: Mielgo-Rubio, Xabier, et al.
Publicado: (2021)

Definitive Bimodality Concurrent Chemoradiotherapy in Patients with Inoperable N2-positive Stage IIIA Non-small Cell Lung Cancer
por: Noh, Jae Myoung, et al.
Publicado: (2015)

Evaluation of safety and efficacy of tivantinib in the treatment of inoperable or recurrent non-small-cell lung cancer
por: Broggini, Massimo, et al.
Publicado: (2013)

Results of systemic treatment of cutaneous melanoma in inoperable stage III and IV
por: Cybulska-Stopa, Bożena, et al.
Publicado: (2013)

Planning target volume as a predictor of disease progression in inoperable stage III non-small cell lung cancer patients treated with chemoradiotherapy and concurrent and/or sequential immune checkpoint inhibition
por: Taugner, Julian, et al.
Publicado: (2021)

Concurrent/sequential versus sequential immune checkpoint inhibition in inoperable large stage III non-small cell lung cancer patients treated with chemoradiotherapy: a prospective observational study
por: Käsmann, Lukas, et al.
Publicado: (2023)

Population-based analysis of curative therapies in stage II non-small cell lung cancer: the role of radiotherapy in medically inoperable patients
por: Moore, Sara, et al.
Publicado: (2020)

Risk‐adapted stereotactic body radiation therapy for central and ultra‐central early‐stage inoperable non‐small cell lung cancer
por: Meng, Mao‐Bin, et al.
Publicado: (2019)

Analysis of the efficacy and safety of iodine-125 seeds implantation in the treatment of patients with inoperable early-stage non-small cell lung cancer
por: Chen, Enli, et al.
Publicado: (2021)

Neoadjuvant Chemoradiotherapy for Stage III Non-Small Cell Lung Cancer
por: Sher, David J.
Publicado: (2017)

Active Surveillance for Medically Inoperable Stage IA Lung Cancer in the Elderly
por: No, Hyunsoo J, et al.
Publicado: (2018)

Hypofractionation and Stereotactic Body Radiation Therapy in Inoperable Locally Advanced Non-small Cell Lung Cancer
por: Rico, Mikel, et al.
Publicado: (2021)

A meta-analysis comparing stereotactic body radiotherapy vs conventional radiotherapy in inoperable stage I non-small cell lung cancer
por: Li, Can, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_jeadbsh7qiqif0khkrgq73al53